{'52WeekChange': 1.2416453,
 'SandP52WeekChange': None,
 'address1': 'Building 1, Jinchuang Plaza',
 'address2': '4th Floor Zhangjiang Hi-tech Park 4560 Jinke Road, Pudong',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 81.11,
 'askSize': 800,
 'averageDailyVolume10Day': 274912,
 'averageVolume': 451619,
 'averageVolume10days': 274912,
 'beta': 1.108214,
 'beta3Year': None,
 'bid': 71.3,
 'bidSize': 1200,
 'bookValue': 4.318,
 'category': None,
 'circulatingSupply': None,
 'city': 'Shanghai',
 'companyOfficers': [],
 'country': 'China',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 76.482,
 'dayLow': 74.04,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -27.191,
 'enterpriseToRevenue': 417.611,
 'enterpriseValue': 5422678528,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 79.359146,
 'fiftyTwoWeekHigh': 89.48,
 'fiftyTwoWeekLow': 29.43,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 40651108,
 'forwardEps': -2.68,
 'forwardPE': -28.36567,
 'fromCurrency': None,
 'fullTimeEmployees': 692,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.07639,
 'heldPercentInstitutions': 0.65759003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/zailaboratory.com',
 'longBusinessSummary': 'Zai Lab Limited, a biopharmaceutical company, engages '
                        'in discovering or licensing, developing, and '
                        'commercializing proprietary therapeutics that address '
                        'medical needs in the fields of oncology, autoimmune, '
                        'and infectious diseases in China. The company offers '
                        'Niraparib, an oral small molecule poly ADP ribose '
                        'polymerase 1/2 inhibitor for the treatment of '
                        'multiple solid tumors, including ovarian and other '
                        'types of lung cancer; and Optune, a cancer therapy '
                        'for the treatment of glioblastoma multiforme. It also '
                        'develops Ripretinib, a switch control inhibitor for '
                        'the treatment of KIT and/or PDGFRa-driven cancers, '
                        'including gastrointestinal stromal tumors, systemic '
                        'mastocytosis, and other cancers; REGN1979 for the '
                        'treatment of diffuse large B-cell lymphoma and '
                        'follicular lymphoma; Margetuximab an immune-optimized '
                        'anti-HER2 monoclonal antibody for the treatment of '
                        'breast and gastric cancers; and INCMGA0012, an '
                        'investigational monoclonal antibody for the treatment '
                        'of MSI-high endometrial cancer. In addition, the '
                        'company develops Bemarituzumab, a humanized '
                        'monoclonal antibody for the treatment of gastric and '
                        'gastroesophageal cancers; Omadacycline, an antibiotic '
                        'to treat acute bacterial skin and skin structure, and '
                        'community-acquired bacterial pneumonia infections; '
                        'and Durlobactam for the treatment of acinetobacter '
                        'baumannii bacterial infections. Zai Lab Limited has '
                        'license and collaboration agreements with the TESARO '
                        'Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, '
                        'Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo '
                        'Biologics Ltd.; Novocure Limited; MacroGenics Inc.; '
                        'Deciphera Pharmaceuticals, LLC; and Incyte '
                        'Corporation. The company was founded in 2013 and is '
                        'headquartered in Shanghai, China.',
 'longName': 'Zai Lab Limited',
 'market': 'us_market',
 'marketCap': 5676831744,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_271123063',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': -195071008,
 'nextFiscalYearEnd': 1640908800,
 'open': 75.77,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '86 21 6163 2588',
 'previousClose': 78.48,
 'priceHint': 2,
 'priceToBook': 17.605373,
 'priceToSalesTrailing12Months': 437.1838,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 76.482,
 'regularMarketDayLow': 74.04,
 'regularMarketOpen': 75.77,
 'regularMarketPreviousClose': 78.48,
 'regularMarketPrice': 75.77,
 'regularMarketVolume': 272045,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 74675504,
 'sharesPercentSharesOut': 0.0369,
 'sharesShort': 2752463,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2452110,
 'shortName': 'Zai Lab Limited',
 'shortPercentOfFloat': None,
 'shortRatio': 5.6,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ZLAB',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.03,
 'twoHundredDayAverage': 63.217697,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '8abb8ada-ed23-324a-aac0-9a720ac3e08a',
 'volume': 272045,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.zailaboratory.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '201210'}